Table 2 Proteins that were statistically significant between early- and advanced-stage ovarian cancers in the discovery (panel A) and the validation sets (panel B), respectively

From: Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers

  

RPPA median intensity values

Protein

P -value

Early stages

Advanced stages

Panel A

4EBP1 S65

0.01

13 095.18

8725.46

Acetyl-CoA carboxylase S79

<0.01

10 625.37

4817.45

AKT T308

<0.01

4272.69

2537.67

AKT S473

<0.01

1718.14

401.02

AMPKα T172

0.05

14 271.22

9302.14

AMPKα1 S485

<0.01

10 198.54

5619.51

AMPKβ1 S108

<0.01

8857.32

6627.61

Bad S112

0.04

2006.20

1136.83

Bad S155

0.04

5089.83

4924.61

FOXO1 S256

<0.01

12 531.49

9643.12

FOXO1 T24/FOXO3 T32

<0.01

26 108.08

12 444.08

GSK-3 α/β S21/9

<0.01

16 514.60

9228.02

IGF-1 RY1135/1136 IR Y1150/1151

0.02

2472.54

1631.08

LC3B

<0.01

2980.96

1271.56

LKB1 S428

0.04

4895.15

3374.49

MDM2 S166

<0.01

14 559.52

9154.49

mTOR S2448

0.04

12 283.35

9163.65

p70S6 Kinase S371

0.03

4167.20

3543.96

p90 RSK S380

0.03

2132.39

595.26

PDK1 S241

0.02

8725.46

5721.58

PRAS40 T246

<0.01

16 139.10

11 544.91

SGK1 S78

<0.01

12 569.14

9566.29

Panel B

Acetyl-CoA carboxylase S79

0.02

11 860.86

6594.56

AMPKα1 S485

0.03

38 948.66

22 247.84

FOXO1 S256

<0.01

38 561.14

26 903.18

FOXO1 T24/FOXO3 T32

<0.01

45 251.91

28 001.12

GSK-3 α/β S21/9

<0.01

52 052.06

29 143.87

MDM2 S166

<0.01

34 891.55

22 247.84

p90 RSK S380

<0.01

18 676.10

29 143.87

PRAS40 T246

0.03

36 680.49

21 829.12

  1. Abbreviation: RPPA=reverse phase protein microarray.
  2. Two-sided non-parametric Wilcoxon rank sum test was used for the discovery set and a one-sided non-parametric Wilcoxon rank sum test was used for the validation set. P-value and median RPPA intensity values for early and advanced stages are reported for each protein.
Back to article page